PLAQUE
Clinical Evaluation of Psoriatic Arthritis Treated With Liraglutide. The PLAQUE Study: Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study
Sponsor study identifier
interventional
0
1 country
1
Study Start
May 2015
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
October 2016
Actual (reported)Study Completion
October 2016
Actual (reported)Exploratory, double-blind randomized, placebo-controlled, Phase II study to evaluate the effect(s) of short-term administration of liraglutide, a GLP-1R (glucagon-like peptide-1 receptor) agonist on joint and skin inflammation in patients with active Psoriatic Arthritis.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2016
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 2015
Date type not reportedThis date has not been verified as actual or estimated.
May 27, 2015
Actual (reported)June 16, 2015
Actual (reported)October 2016
Actual (reported)October 2016
Actual (reported)The change in the proportion of patients achieving an ACR 20% improvement response in patients with psoriatic arthritis receiving liraglutide for 12 weeks compared to placebo
Proportion of patients achieving an ACR (American College of Rheumatology) 20% improvement response. ACR 20 is a composite rheumatological endpoint which includes swollen joint count, tender joint count, pain, physician global assessment, patient global assessment, HAQ (health assessment questionnaire), CRP (c reactive protein).
Baseline to 12 weeks, liraglutide compared to placebo
The change in the psoriasis area and severity index (PASI) in patients with psoriatic arthritis receiving liraglutide for 12 weeks compared to those receiving placebo
Baseline to 12 weeks
liraglutide 0.6mg sc daily for 1 week, 1.2mg sc daily for 11 weeks
Placebo sc daily for 12 weeks, volume titration at week 2 to mirror liraglutide arm
Liraglutide 0.6mg sc daily for 1 week, 1.2mg sc daily for 11 weeks
Placebo sc daily for 12 weeks, volume titration at week 2 to mirror liraglutide arm
Toronto Western Hospital, The Centre for Prognosis Studies in the Rheumatic Diseases (CPSRD), University of Toronto
Toronto, Ontario, M5T 2S8, Canada
0 participants (actual enrollment reported by the registry).
First Submitted
May 27, 2015
First Posted
June 16, 2015
Study Start
May 2015
Date type not reportedThis date has not been verified as actual or estimated.
Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes
The change in quality of life measured by validated quality of life questionnaires in patients with psoriatic arthritis receiving liraglutide for 12 weeks compared to those receiving placebo
Baseline to 12 weeks
The change in glucose tolerance in patients with psoriatic arthritis with glucose intolerance at baseline who receive liraglutide for 12 weeks compared to those receiving placebo
Baseline to 12 weeks
The effect(s) of liraglutide on cardiovascular disease risk factors in patients with psoriatic arthritis receiving liraglutide for 12 weeks compared to those receiving placebo
Baseline to 12 weeks
The effect(s) of liraglutide on the enumeration of circulating T-cell subpopulations, and on activation of circulating T-cell subpopulations
Baseline to 12 weeks
The effect of liraglutide on levels of infiltrating dermal T cells and cytokines in psoriatic skin plaques from patients with psoriatic arthritis receiving liraglutide therapy for 12 weeks compared to those receiving placebo
Baseline to 12 weeks
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
October 2016
Actual (reported)Study Completion
October 2016
Actual (reported)Last Updated
July 17, 2017
Record last verified: 2015-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: